Your browser doesn't support javascript.
Pulmonary function and health-related quality of life after COVID-19 pneumonia.
van der Sar-van der Brugge, S; Talman, S; Boonman-de Winter, Ljm; de Mol, M; Hoefman, E; van Etten, R W; De Backer, I C.
  • van der Sar-van der Brugge S; Amphia Hospital, Department of Pulmonary Medicine, Postbus 90158, 4800 RK Breda, the Netherlands. Electronic address: svandersar@amphia.nl.
  • Talman S; Amphia Hospital, Department of Pulmonary Medicine, Postbus 90158, 4800 RK Breda, the Netherlands.
  • Boonman-de Winter L; Amphia Hospital, Amphia Academy, Postbus 90158, 4800 RK Breda, the Netherlands.
  • de Mol M; Amphia Hospital, Department of Pulmonary Medicine, Postbus 90158, 4800 RK Breda, the Netherlands.
  • Hoefman E; Revant, Centre for Rehabilitation, Brabantlaan 1, 4817 JW Breda, the Netherlands.
  • van Etten RW; Amphia Hospital, Department of Internal Medicine, Postbus 90158, 4800 RK Breda, the Netherlands.
  • De Backer IC; Amphia Hospital, Department of Pulmonary Medicine, Postbus 90158, 4800 RK Breda, the Netherlands.
Respir Med ; 176: 106272, 2021 01.
Article in English | MEDLINE | ID: covidwho-953095
ABSTRACT

BACKGROUND:

The COVID-19 pandemic has led to many cases of pneumonia with extensive lung abnormalities on CT-scans. The consequences of COVID-19 pneumonia on survivors' pulmonary function and quality of life are unknown. The purpose of this study is to examine the impact of COVID-19 pneumonia on pulmonary function, health-related quality of life (HRQoL) and perceived dyspnoea.

METHODS:

A prospective longitudinal cohort study regarding patients discharged from our hospital after PCR-proven, non-critical COVID-19 pneumonia was conducted. Cases were classified as moderate or severe pneumonia according to WHO definitions. Six weeks post-discharge subjects underwent interviews and pulmonary function tests, and completed questionnaires to assess their HRQoL, perceived dyspnoea (Borgscale and mMRC), and symptoms of depression and anxiety (HADS).

RESULTS:

101 patients were included. Twenty-eight (27.7%) pneumonias were classified as moderate cases of COVID-19 pneumonia and 73 (72.3%) were classified as severe cases. Diffusion limitation (DLCOc < 80% of predicted value) was found in 66 (71.7%) of 92 cases, obstruction in 26 (25.7%) of 101, and restriction in 21 (21.2%) of 99. Diffusion capacity was significantly lower in cases after severe pneumonia. In the entire group, HADS scores ≥8 for depression were found in 16.6% and in 12.5% for anxiety. Across all SF-36 domains, except for bodily pain, significant impairment was found. FEV1 and DLCOc showed significant positive correlations with mMRC scores and multiple SF-36 domains, especially physical functioning.

CONCLUSION:

COVID-19 non-critical pneumonia survivors have significant impairment in diffusion capacity and HRQOL six weeks after being discharged from hospital.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Quality of Life / COVID-19 / Lung Type of study: Cohort study / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Quality of Life / COVID-19 / Lung Type of study: Cohort study / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Respir Med Year: 2021 Document Type: Article